House Committee on Health and Human Services

As Amended by Senate Committee

Session of 2021

SENATE BILL No. 200

By Committee on Public Health and Welfare

2-10

AN ACT concerning pharmacists and pharmacy; relating to the state board of pharmacy; expanding the pharmacist's scope of practice to include point-of-care testing for and treatment of certain health conditions; amending K.S.A. 65-1626a and repealing the existing section.

4 5 6

7

8

10

11

12

13

14

15

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

35 36

2

3

Be it enacted by the Legislature of the State of Kansas:

New Section 1. A pharmacist may independently test or screen for and initiate therapy pursuant to a state-wide protocol established by the state board of pharmacy for health conditions of individuals who are eligible to receive the testing or screening service. For purposes of this section, a health condition is a condition that is generally managed with minimal treatment or self-care and includes, but is not limited to:

- (a) Influenza;
- (b) streptococcus;
- (c) COVID-19;
- 16 (d) pre-exposure prophylaxis;
 - (e) post-exposure prophylaxis; or
 - (f) a condition for which its diagnostic test is waived under the federal clinical laboratory improvement amendments of 1988.

New Section 1. (a) A pharmacist may initiate therapy within the framework of a statewide protocol for the following health conditions:

- (1) Influenza;
- (2) streptococcal pharyngitis; or
- (3) urinary tract infection.
- (b) The collaborative drug therapy management advisory committeemay adopt a statewide protocol for each condition listed in subsection (a). The committee shall consider appropriateness of therapy basedupon:
 - (1) The patient's age;
- (2) approval by the United States food and drug administration;
- (3) in-person interactions; and
- (4) the method of administration. -

Sec. 2. K.S.A. 65-1626a is hereby amended to read as follows: 65-1626a. (a) For the purpose of the pharmacy act of the state of Kansas, the following—persons *individuals* shall be deemed to be engaged in the practice of pharmacy:

established pursuant to K.S.A. 65-1677, and amendments thereto,

[stricken material in lines 27 through 32]

In establishing such statewide protocols, the committee shall specify:

- (1) The medications or categories of medications included in the protocol for each health condition;
- (2) the training or qualifications required for pharmacists to implement the protocols;
- (3) requirements for documentation and maintenance of records, including patient inclusion and exclusion criteria, medical referral criteria, patient assessment tools based on current clinical guidelines, follow-up monitoring or care plans and the pharmacist's adherence to the applicable protocols; and
- (4) communication requirements, including, but not limited to, notification to the patient's personal or primary care provider.
- (c) The board may deny an application or renewal or revoke or suspend the license of a pharmacist upon a finding that the pharmacist has violated the provisions of this section or failed to practice within the framework of statewide protocols established by the collaborative drug therapy management advisory committee.